NewCardio Expert to Present at Cardiac Safety Research Consortium Annual Meeting
SANTA CLARA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Sam George, NewCardio's Senior Consultant, will join a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in Maryland at the Marriot Bethesda, Pooks Hill location on October 29-30, 2009. Dr. George, a cardiologist, was formerly Professor of Medicine and Pharmacology at Duke University Medical Center, and Director of Medical Affairs at CV Therapeutics, Inc. He is an Established Investigator of the American Heart Association.
The CSRC (www.cardiac-safety.org) is a broad-based collaboration of medical product safety experts from academia, industry, and the US Food and Drug Administration (FDA). It was formed in 2005 in response to the Critical Path Initiative, the FDA's premier effort to modernize the drug development process. The CSRC's primary goal is to facilitate development of new tools to improve cardiac safety assessment of medical products, especially tools to quantify arrhythmia (abnormal heart beat) risk of new drugs in development. With the FDA, the CSRC established a centralized ECG warehouse of ECGs obtained from drug clinical research studies.
Dr. George will make a presentation on the role of the CSRC's ECG warehouse from the point of view of a vendor. As part of this presentation, he is expected to present some of NewCardio's clinical validation data from several Phase I studies, including Thorough QT (TQT) studies based on 12-Lead ECG and full 24 hour Holter ECG data. In addition, he expects to discuss the true potential of the CSRC-FDA ECG Warehouse, and the steps the industry can take to achieve these goals. Following the presentation, Dr. George will participate in a discussion panel.
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "NewCardio remains committed to the CSRC and we believe this organization has and will continue to help advance methods and solutions to improve cardiac safety in drug development. As an organization, we are excited to participate in this annual meeting and we endeavor to assist this organization in any way we can."
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
SOURCE NewCardio, Inc.